BMN

AcronymDefinition
BMNBiomednet (former website)
BMNBureau de Mise a Niveau (French: Upgrading the Office)
BMNBurke Mountain Naturalists
BMNBerenstein-Maldacena-Nastase (matrix model)
BMNBrand Medically Necessary
BMNBleu Medical Needle (mesopuncture product)
BMNBenesh Movement Notation
BMNBamerny Airport (airport code; Iraq)
BMNBrian's Morning Newsletter (blog; est. 1999)
BMNBrigade Multinational
BMNBeat Mike Network (online game)
BMNBuilding Management Network
BMNBanc de Mesure de Niveau (French: Bench Level Measurement)
BMNBeatmakernation (French website and forum)
BMNBenign Melanocytic Naevus (skin disorder)
References in periodicals archive ?
BMN is also in the process of deploying an operational dashboard for its 4,700 employees to analyze branch activity and react to trends and outlier data quickly using their iPad devices.
If the median nerve was divided into two branches proximal to the carpal tunnel, it was considered as BMN (Figure 1).
BMN 673, which is yet to be given a trade name, is one of a handful of a family of molecules called PARP inhibitors which are under development.
Thus, BMN will reduce its financial needs, estimated at EUR 2.
BMN : Le Burkina a pour principe diplomatique la politique de bon voisinage.
BMN is a privately-owned British company that develops web based applications using Microsoft technology.
Like any language, BMN is a system of communication that lives and breathes.
In mid-2015, BioMarin predicts to start clinical studies with BMN 250.
BMN is using the brand of Caixa Penedes, one of the four savings banks that had set up the bank, in Catalonia and Aragon.
With almost three million customers, BMN is a financial group resulting from the integration of Cajamurcia, CajaGranada and Sa Nostra, which makes it the market share leader in the Spanish geographic areas.
Established in 2001 as a digital signage company, BMN has focused on creating brand and retail specific programs driven by a proprietary hardware and software solution.
PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers.